Home » Newsletters » BioWorld Science

BioWorld Science

Dec. 30, 2003

View Archived Issues

CBT-1008 manufactured for preclinical studies

PVAC development for psoriasis discontinued

Approvable letter for Inspire's diquafosol tetrasodium ophthalmic solution

Novacea stops enrollment in DN-101 trial for MDS

Canadian notice of noncompliance for Statex

CPMP rejects PharmaMar appeal regarding Yondelis

Connetics submits NDA for Actiza

Eisai submits MAA for rapid dissolve Aricept in U.K.

GTI-2501 enters phase II

Sixteenth Medarex fully human antibody enters clinical development

Pivotal urban ambulance trial cleared to begin for PolyHeme(R)

PMA filing commences for OrCel for venous leg ulcers

Phase III doripenem trial commences enrollment

Enrollment completed in phase IIa study of PCK-3145

European orphan drug designation for gimatecan for glioma

Topical tacrolimus reported effective for oral lichen planus and facial psoriasis

Potential clinical benefits of CAI in ovarian cancer

France is first country to approve oral thrombin inhibitor

Series of phosphonates able to modulate apolipoprotein E described by Ilex

New stimulators of guanylate cyclase described in Bayer patent

New King Pharmaceuticals patent claims adenosine A3 receptor antagonists

Broad spectrum antiparasitics prepared at the University of Mississippi

Otsuka describes novel thiourea derivatives for diabetes and obesity

Tributyrin induces apoptosis of leukemia cell lines

FR-181157 shows potent PGI2 agonist activity and good pharmacokinetic profile

JNJ-10329670 represents a new class of immunosuppressive compounds

Health officials prepare for SARS resurgence, review treatment options

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld
Parkinson’s disease is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder, and...
First-in-class pan-inflammasome blocker for hidradenitis suppurativa
BioWorld Science
Researchers from Paratus Sciences Corp. presented the preclinical profile of PS-1001, a novel pan-inflammasome inhibitor designed to prevent IL-1β and IL-18 release.
RX-10616 improves radiotherapy efficacy in HNSCC
BioWorld Science
Head and neck squamous cell carcinoma (HNSCC) accounts for high number of new diagnoses each year. Current management is based on surgery followed by radiotherapy...
CROI 2026: Neurodegeneration, the challenge of aging with HIV
BioWorld
Antiretroviral therapies against HIV have been in use for more than 30 years and have enabled people living with HIV to maintain undetectable viral levels. Many...